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Rats neonatally treated with monosodium L-glutamate (MSG) are deeply dysfunctional in adulthood. We explored the effect of an
oral low dose of metformin treatment in male MSG rats on adipoinsular axis and visceral adipose tissue (VAT) dysfunctions,
in both basal (nonfasting) and endotoxemia conditions. MSG rats, treated or not treated with metformin (30 days prior to
experimentation), and control litter-mates (CTR) were studied at 90 days of age. Peripheral concentrations of glucose, lipids, and
hormones were determined in basal and post-lipopolysaccharide (LPS) treatment conditions. Food intake and body weight (BW)
were recorded and VAT mass and leptin mRNA levels were evaluated. Data indicated that MSG rats were lighter and displayed
hypercorticosteronemia, hypophagia, adipoinsular axis hyperactivity, and enhanced VAT mass associated with an increased leptin
gene expression. Interestingly, metformin-treatedMSG rats corrected BW catch-up and counteracted VAT (mass and leptinmRNA
level) and adipoinsular axis (basal and post-LPS) dysfunctions. Thus metformin treatment in MSG rats is able to correct several
VAT and metabolic-endocrine dysfunctions. Our study suggests that a low-dose metformin therapy is effective to correct, at least
in part, adipoinsular axis dysfunction in hypertrophic obese phenotypes, such as that of the human Cushing syndrome.
1. Introduction
Neonatal monosodium L-glutamate (MSG) administration
induces morphological, behavioral, and neuroendocrine
abnormalities such as growth disturbances, self-mutilation,
hyperadiposity, and hypogonadism [1–4]. It has been assessed
that catecholaminergic and peptidergic neuronal loss takes
place in the retina and hypothalamic arcuate nucleus (ARC)
[4–6]. As a consequence, body’s energy balance [7–9], pitu-
itary [10–12], and adrenal [13] activities become disrupted.
A conspicuous effect of MSG-induced hypothalamic damage
is an overall enhanced response of median eminence (ME)
neuron terminals [10–12]. Thus, extensive brain damage has
been ascribed to explaining neuroendocrine malfunctions in
this model [14–16]. Acute inflammatory stress affects anterior
pituitary hormone secretion by mechanisms involving differ-
ent hypothalamic neuronal systems [17–21], already altered
in the MSG animal model [4–6]. The ARC is a pivotal
structure involved in the regulation of energy storage and
expenditure [22], and both adipose tissue leptin secretion
and hypothalamic leptin signaling system play key roles in
maintaining homeostasis [22]. Among others, MSG rats are
hyperleptinemic [23] due to hypertrophic adipose tissue (AT)
mass expansion [24]. MSG rats are partly refractory to leptin
inhibition of food intake and body weight gain [25], and
overall leptin resistance seems to be directly dependent on
enhanced glucocorticoid production [13, 26].
We previously reported that the adult male MSG rat
displays neuroendocrine-immune dysfunction during the
acute phase response of endotoxemia [27]. In the present
study we explored in the MSG male rat model whether met-
formin treatment could be effective to ameliorate endocrine-
metabolic-immune dysfunction, in both basal and post-
lipopolysaccharide (LPS) administration conditions.
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2. Material and Methods
2.1. Animals and Treatment. Adult male and female Sprague-
Dawley rats were allowed to mate in colony cages in a light-
(lights on from 07:00 to 19:00 h) and temperature- (22∘C)
controlled room. Rat chow and water were available ad
libitum. Pregnant rats were transferred to individual cages.
Beginning on day 2 after parturition, newborn pups were
injected i.p. with either 4mg/g body weight (BW) MSG
(SigmaChemical Co., St. Louis,MO) dissolved in sterile 0.9%
NaCl or 10%NaCl (litter-mate controls; CTR) once every two
days and up to day 10 of age [12]. Rats were weaned and sexed
at 21 days of age, and male animals (CTR and MSG) were
group-caged (3 rats per cage) and supplied with Purina chow
and water ad libitum. Animals were left undisturbed until 59
days of age. CTRandMSGratswere used for experimentation
on day 90 of age. MSG-injected animals were screened for
effectiveness of treatment by macroscopic observation of
degeneration of the optic nerves at the time of sacrifice and
monitoring medial basal hypothalamic (MBH) levels of NPY
mRNA. Animals were sacrificed according to protocols for
animal use, in agreement with NIH Guidelines for care and
use of experimental animals. All experimentation received
approval from our institutional animal care committees.
2.2. Experimental Designs. On day 59 of age, rats were
individually caged, and daily BW and food intake were
recorded between days 60 and 90 of age. Experimental groups
(𝑛 = 18 rats per group) were (i) CTR, (ii) MSG, and (iii) MSG
animals receiving metformin (Craveri Lab., Argentina; at the
dose 50mg/Kg/day, dissolved in the drinking water, between
days 60 and 90 of age; MSG + metformin) [28].
Experiment 1. Rats were sacrificed on the morning of the
experimental day (90 days of age; 8 individuals per group)
in nonfasting (basal) condition. Trunk blood was collected
and plasma samples were kept frozen (−80∘C) until assayed
for glucose [27], nonesterified fatty acids (NEFA; Randox
Laboratories Ltd., UK), triglycerides [27], corticosterone (B)
[27], leptin [27], and insulin [27], by following the previously
specific assays. Immediately after sacrifice, the MBHs were
quickly dissected [21] and kept frozen (−80∘C) until total
RNA extraction. Thereafter, the visceral adipose tissue (VAT;
abdominal pad) was dissected, weighed, and kept frozen
(−80∘C) until total RNA extraction. While the mRNA levels
of neuropeptide Y (NPY) were evaluated in the MBH, those
of leptin (LEP) in the VAT pad were measured.
Experiment 2. Rats were implanted, 48 hours before exper-
imentation and under light ketamine anesthesia, with iv
catheters and left undisturbed in individual cages, with food
and water available ad libitum. On the morning (08:00 h)
of the experimental day (90 days of age; 8 individuals
per group), rats were bled before (between 2 and 5min
pretreatment; sample time zero) and 1, 2, 3, and 4 hours
after i.v. administration of a sublethal dose of bacterial LPS
(25 𝜇g/Kg; Sigma Chem. Co.) [29]. As described, blood
samples taken were replaced by a similar volume of red blood
cells resuspended in artificial plasma [29]. Plasma samples
were split in aliquots and kept frozen (−80∘C) until assayed
for glucose [27] and triglycerides [27] concentrations.
2.3. Tissue RNA Isolation and qRT-PCR (Quantitative Real-
Time PCR). Total RNA was isolated from tissues (MBH
blocks and VAT pads) by the single-step acid guanidinium
isothiocyanate-phenol-chloroform extraction method (Tri-
zol; Invitrogen, Life Tech.,USA;Cat. number 15596-026) [30].
One 𝜇g of total RNA was reverse-transcribed using random
primers (250 ng) and Superscript III RNase HReverse Tran-
scriptase (200U/HL Invitrogen, Life Tech, USA; Cat number
18989-093). Two 𝜇L of reverse transcription mix was ampli-
fied with 10 𝜇L of QuantiTect SYBRGreen PCR solution kit
(Qiagen, Cat. number 204143), in the presence of 1𝜇L of each
specific primer (0.5 𝜇M final concentration), and revealed
using a LightCycler Detection System (MJ MiniOpticon,
Biorad). Primers (shown in alphabetical order in Table 1)
were 𝛽-actin (ACTB), LEP, and neuropeptide Y (NPY). PCR
efficiency was near to 100%. Threshold cycles (Ct) were
measured in separate tubes, in duplicate. Identity and purity
of the amplified product were checked by electrophoresis
on agarose mini-gels and the melting curve was analyzed at
the end of amplification. The differences between Cts were
calculated in every sample for each gene of interest as follows:
Ct gene of interest—Ct ACTB gene. Relative changes in the
expression level of a specific gene (ΔΔCt) were calculated as
ΔCt of the test group minus ΔCt of the CTR group and then
expressed as 2−ΔΔCt.
2.4. Statistics. Data are expressed as mean ± SEM. Means
were analyzed by two-way ANOVA (either with repeated
measures or not), followed by the Student-Newman-Keuls
test for comparison of different means. Results of tissue
mRNA concentrations were analyzed by ANOVA and the
nonparametric Mann-Whitney test [31].
3. Results
3.1. Rat Phenotype. Departing (age 60 days) BW values
already indicated that MSG rats were lighter than CTR rats
(216.83 ± 7.15 versus 245.38 ± 9.28 g, resp.; 𝑃 < 0.05). On
this day, animals were individually caged, andMSG rats were
allocated in two subgroups according to whether they were
orally treated or were not treated with metformin (MSG +
metformin and MSG rats, resp.). On the experimental day
(90 days of age), MSG rats displayed significantly (𝑃 <
0.05) lower BWs than CTR rats; conversely, metformin-
treated MSG rats (MSG + metformin) reached this day with
indistinguishable BWs from those of CTR rats (Figure 1(b)).
The slopes (expressed in percent of increase per day) of the
30-day growing curves (Figure 1(a)) indicated that MSG rats
grew slower (1.13 ± 0.04) than CTR rats (1.35 ± 0.08) (𝑃 <
0.03); interestingly, the stunted growth displayed by MSG
animals was fully corrected by metformin treatment (1.21 ±
0.02; 𝑃 > 0.05 versus CTR values).
As depicted in Figure 1(c), MSG rats that were or were
not treated with metformin displayed hypophagia when
compared with CTR rats. Indeed, the daily rat food intake
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Table 1: Rat-specific primers (in alphabetical order) designed and used for real-time PCR analyses.
GBAN bp
ACTΒ se, 5
󸀠-AGCCATGTACGTAGCCATCC-3󸀠 NM 031144 115
as, 5󸀠-ACCCTCATAGATGGGCACAG-3󸀠
LEP se, 5
󸀠-GAGACCTCCTCCATCTGCTG-3󸀠 NM 013076 192
as, 5󸀠-CTCAGCATTCAGGGCTAAGG-3󸀠
NPY se, 5
󸀠-TACTCCGCTCTGCGACACTA-3󸀠 NM 012614 115
as, 5󸀠-GGGCATTTTCTGTGCTTTCT-3󸀠
se: sense; as: antisense; GBAN: GenBank Accession Number; amplicon length, in bp.
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Figure 1: Animal growing curves drawn throughout ages 60 to 90 days (a) and body weight values recorded at age 90 days (b) in different
groups of experimental animals. Daily food intake registered between 60 and 90 days of age (c) and the 30-day average of daily food intake
and body weight values recorded at age 90 days (d) in CTR, MSG, and MSG +metformin (MSG +MF) rats. Values means ± SEM (𝑛 = 8 rats
per group). ∗𝑃 < 0.05 or less versus CTR values.
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Figure 2: Visceral adipose tissue (VAT)mass (a) andmRNA levels (in arbitrary units, AU) of leptin (b) in 90-day-oldCTR andMSG-damaged
male rats, either treated or untreated with metformin (MSG + MF). Values are means ± SEM (𝑛 = 4-5 pads per group). †𝑃 < 0.05 versus
MSG values. ∗𝑃 < 0.05 versus CTR values.
(expressed as the 30-day average, after recorded between ages
61 and 90 days) was significantly (𝑃 < 0.0001) lower in
MSG rats, either treated or untreated with metformin, than
in CTR animals (Figure 1(d)).The hypophagia characterizing
MSG rats concords with the lower abundance of NPYmRNA
in their MBHs. In fact, MBH NPY mRNA was significantly
reduced inMSG rats, regardless whether or not they received
metformin treatment (0.47 ± 0.22 versus 1.02 ± 0.37 arbitrary
units; 𝑃 < 0.03).
3.2. Effect of Metformin Treatment on Visceral Adipose Tissue
Mass and Leptin Gene Expression. The VAT pad mass was
higher (𝑃 < 0.05) in MSG (8.02 ± 0.41 g) than in CTR (4.03 ±
0.22 g) rats, and metformin treatment (MSG + metformin
rats) was effective to significantly (𝑃 < 0.05 versus MSG
and CTR group-values) reduce this parameter (6.02 ± 0.71 g).
Indeed, relative to individual BW values, the VAT pad mass
was 1.8-fold (𝑃 < 0.01) higher in MSG than in CTR rats, and
metformin treatment in MSG rats (MSG + metformin) was
able to significantly (𝑃 < 0.05 versus MSG values) reduce
VAT mass, although mass values remained significantly (𝑃 <
0.05) higher than in CTR animals (Figure 2(a)).
Figure 2(b) shows the results of VAT mRNA levels of
leptin in different groups. As depicted, VAT leptin mRNA
concentration was severalfold higher in MSG than in CTR
rats (𝑃 < 0.001). Interestingly, metformin treatment in
MSG rats resulted in a significant (𝑃 < 0.01) reduction in
the expression levels of the leptin gene in their VAT pads,
although values remained higher (𝑃 < 0.02) than inCTR rats.
3.3. Peripheral Biomarkers. MSG animals studied in the basal
(nonfasting) condition displayed an expected hypercorticos-
teronemia (13.92 ± 1.75 and 12.03 ± 1.57 𝜇g/dL in MSG and
MSG+metformin rats, resp., versus 6.38 ± 1.26 𝜇g/dL in CRT
rats; 𝑃 < 0.05).
Analysis of the adipoinsular axis activity indicated that
although glycemia was similar in all groups studied (101 ±
7, 107 ± 4, and 102 ± 5mg/dL in CTR, MSG, and MSG +
metformin groups, resp.), significantly (𝑃 < 0.05 versus
CTR values) higher insulinemia was noticed in MSG than
in CTR rats (Figure 3(a)). Interestingly, metformin treatment
in MSG rats was able to significantly (𝑃 < 0.05 versus
MSG group-values) reduce insulinemia, its values being now
similar to those displayed by CTR animals (Figure 3(a)). As
expected [27], MSG rats displayed severe hyperleptinemia
(𝑃 < 0.05 versus CTR values) (Figure 3(b)); however, this
adipose tissue dysfunction characterizing MSG rats was fully
(𝑃 < 0.05 versus MSG values) abolished by metformin
treatment (Figure 3(b)). Finally, MSG rats displayed normal
basal NEFA and TG circulating levels (Figures 3(c) and 3(d),
resp.), and metformin treatment in MSG rats significantly
(𝑃 < 0.05) reduced plasma lipids levels (Figures 3(c) and
3(d)).
3.4. Glycemic and Triglyceridemic Profile throughout Acute
Endotoxemia. Figure 4 shows the results of circulating glu-
cose and triglycerides concentrations before (sample time
0) and several times (1–4 h) after endotoxemia. LPS i.v.
administration did not induce any significant hypoglycemia
in neither experimental group. Indeed, as depicted, cir-
culating glucose levels (Figure 4(a)) were similar among
groups in different times examined, and all groups displayed
no significant time-dependent changes in plasma glucose
concentrations when comparing values from the AUC of
glycemia (Figure 4(b)).
Although basal triglyceridemia (Figure 4(c)) was similar
in CTR andMSG groups, a significantly (𝑃 < 0.05) decreased
basal lipid concentration was shown in MSG + metformin
rats. LPS administration significantly (𝑃 < 0.05 versus
respective time 0 values) enhanced triglyceridemia in CTR
rats for the 3 h after LPS, thereafter returning to basal levels
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Figure 3: Circulating levels of markers of the adipoinsular axis function: insulin (a), leptin (b), nonesterified fatty acids (NEFA) (c), and
triglycerides (TG) (d), in normal (CTR), MSG, and metformin-treated MSG (MSG + MF) male rats at 90 days of age. Values are means ±
SEM (𝑛 = 8 rats per group). †𝑃 < 0.05 versus MSG values. ∗𝑃 < 0.05 versus CTR values.
by the end of the test. Conversely, in MSG rats, plasma lipid
levels were already significantly (𝑃 < 0.05 versus respective
time 0 values) higher than the 2 h after LPS, and this
effect lasted until the end of the experimental design (4 h).
Interestingly, metformin treatment in MSG rats delayed the
enhancement in plasma lipid concentration up to a similar
time to that occurring in CTR rats (3 h); however, these rats
did not recover their basal TG levels by the end of the test.
Moreover, the AUC of triglycerides values was significantly
(𝑃 < 0.01) higher in MSG than in CTR rats (Figure 4(d)).
Interestingly, metformin treatment in MSG rats was able
to partially prevent the enhanced lipidic response to LPS
injection, as depicted by the AUC values of peripheral TG
levels (Figure 4(d)).
4. Discussion
Our study indicates that MSG-induced neonatal hypothala-
mic damage resulted in the alteration of endocrine-metabolic
function at the adult age and, importantly, that this multidys-
function can be improved by the treatment with a very low
dose of metformin.
It should be stressed that although several dysfunctions in
the adultmaleMSG rat, a phenotype of hypothalamic obesity,
have been extensively revisited [1–13], only few studies have
been focused on the metabolic improvement induced by
metformin treatment in these animals. Indeed, data from
previous studies performed in MSG rats treated with a high
daily metformin dose (300–500mg/Kg BW) [32–34] indicate
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Figure 4: Peripheral levels of glucose (a) and triglycerides (c) before (time zero hours) and several hours after i.v. LPS (25mg/Kg BW)
treatment in different groups of rats.The area under the curve (AUC) of glycemia (b) and triglyceridemia (d) throughout endotoxemia is also
displayed. Values are means ± SEM (𝑛 = 8 rats per group). a𝑃 < 0.05 versus time 0 values in the same group. ∗𝑃 < 0.05 versus CTR values
for a similar time. †𝑃 < 0.05 versus MSG values for a similar time.
that the treatment improves glucose metabolism [32–34],
blood pressure [34], and cardiovascular function [31, 32].
The analysis of our animals’ phenotypes indicated that,
although all MSG rats remained hypophagic, their overall
stunted growth (growing curve, low body weight, and large
adiposity) was significantly ameliorated by metformin treat-
ment.Thus, such an improvement is clearly indicative for the
occurrence of favorable, metformin-dependent, metabolic-
endocrine changes in MSG animals. Indeed, it has been
reported that metformin treatment in high-fructose fed rats
resulted in being able to reduce intra-abdominal adipose
tissue mass by activating local sympathetic activity at the
retroperitoneal adipose tissue level [35]. Taken into account
that theMSG rat is characterized by an impaired sympathetic
[36] and adrenal [37] catecholamine production, this met-
formin effect could highly contribute to reducing VAT mass
by its increasing effect in sympathetic activity [35]. Moreover,
and agreeingwith our findings,metformin treatment in high-
fat fed rats is able to improve metabolism and to reduce body
fat mass, without affecting food intake and body weight [38].
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In this regard, the adiposity dysfunction, namely that
developed at the VAT level, in MSG rats was highly improved
by the oral treatment of animals with a very low dose of
metformin. Indeed, the high peripheral levels of insulin
and leptin in the nonfasting condition (two metabolically
different paths belonging to the adipoinsular axis) in MSG
rats were fully corrected bymetformin treatment. In addition,
we have addressed thatmetformin treatment inMSG animals
also was able to improve VAT dysfunction, such as tissue
mass and leptin mRNA concentration. Accordingly, we have
recently addressed that the treatment with enhancers of
insulin activity, although in a model of diet-induced hyper-
adiposity, was effective in preventing hyperinsulinemia, dys-
lipidemia, hypertrophic expansion of abdominal adipose tis-
suemass, and adipocyte leptinmRNA overexpression, whose
mechanisms were mainly mediated by the improvement of
both IRS-1 and IRS-2 functionalities after metformin [39].
Regarding the lipidic metabolism in MSG rats, although
there are some discrepancies among our data on unmodified
peripheral TG concentrations, it must be mentioned that
other researchers found enhanced basal TG levels where they
have taken those samples at 8 or more hours after food
was withdrawn (fasting condition) [40, 41]. When analyzing
peripheral TG levels in response to LPS in MSG rats, it
has been shown that MSG rats, over development, display
reduced lipolytic and enhanced lipogenic activities [42],
thus indicating that after the allostatic load (LPS injection)
the balance of activities strongly support for the enhanced
MSG AUC of this lipid [43, 44]. Moreover, other authors
reported that metformin treatment in either high lipid- or
high fructose-fed rats was able to prevent the development
of oxidative stress and thus hyperlipidemia/-insulinemia [45,
46]. Indeed, a direct metformin reducing effect on NEFA
production by isolated adipocytes has also been detected
[47]. Interestingly, in the present experiments we found that,
despite no changes in glycemia, the increased LPS-induced
triglycerides secretion in plasma in MSG rats was also fully
abolished by metformin treatment. It has been reported
that metformin could reduce peripheral dyslipidemia by an
indirect mechanism, related to diminished synthesis and
enhanced clearance of VLDL particles [48], the main TG
transporter in the circulation.
In relation with the intriguing lack of a peripheral glucose
response, we previously found an increase in peripheral
insulin levels after LPS treatment in rats [27]. Moreover,
LPS treatment in MSG rats enhances also the secretion of
immune system-derived cytokines and pancreatic insulin,
and as a counterregulatory signal, glucagon; thus, the ratio of
peripheral insulin : glucagon concentrations remains similar
to that displayed by LPS-injected normal rats [27]. Moreover,
animals under endotoxemia also develop an increase in
glucocorticoid production that precedes that of insulin [27];
thus the enhanced glucocorticoid endogenous environment
could be cooperating for maintaining glucose homeostasis
[49], a phenomenon vital for survival during endotoxic
shock.
Regarding the adipoinsular axis response to LPS, it is
well known that in normal rats this stimulus enhances
the secretion of both leptin [29] and insulin [50], and we
previously found that in MSG rats such a response is clearly
exacerbated [27]. Moreover, hyperleptinemic MSG rats also
displayed basal hyperinsulinemia, agreeing with data from
previous in vivo studies from our laboratory [27, 51] and with
in vitro studies suggesting that in MSG rats the parasym-
pathetic regulation of pancreatic activity is increased [52].
Interestingly, metformin treatment in MSG was able to fully
reverse hyperinsulinemia and hyperleptinemia in the basal
condition. The mechanism whereby this metformin effect
takes place has been ascribed to its intrinsic inhibition of liver
glucose production (directly related to insulinemia) and to a
VATmass lowering effect. Indeed, metformin administration
in MSG did also result in a significant decrease in leptin
mRNA abundance in their VAT pads. The decrease in VAT
mass and the reduced insulinemia and leptinemia induced
by metformin treatment in MSG rats also could benefit the
LPS-induced dyslipidemia.
In conclusion, our study demonstrates that many of the
host’s defense mechanisms are deeply disturbed in MSG rats
and are of relevance, so that a very low oral dose ofmetformin
during one month is able to ameliorate this rat phenotype.
It is largely accepted that the main site of MSG action is
the ARC and that not only NPYergic [26] but also other
hypothalamic neuronal activities are impaired in MSG rats
[43, 53]. Nevertheless, despite a lack of effect of metformin
on food intake, treating MSG rats with a very low dose of
this compound did result in a significant improvement in
body weight catch-up (displaced to a lower fat mass) and
several metabolic-endocrine dysfunctions, namely those of
the adipoinsular axis. Thus, our study adds more evidence
to the efficacy of metformin treatment for lowering cardio-
vascular risk in hyperadipose phenotypes characterized by
an excess of endogenous glucocorticoid, as occurs in human
Cushing’s syndrome [44]. It remains to be further explored
whether a larger metformin dose could be effective to correct
(partly/fully) hypercorticosteroidism in MSG rats.
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